OCULAR THERAPEUTIX INC's ticker is OCUL and the CUSIP is 67576A100. A total of 130 filers reported holding OCULAR THERAPEUTIX INC in Q3 2022. The put-call ratio across all filers is 0.55 and the average weighting 0.9%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $378,562 | +55.3% | 120,561 | +155.2% | 0.00% | – |
| Q2 2023 | $243,743 | -5.7% | 47,237 | -3.7% | 0.00% | – |
| Q1 2023 | $258,530 | +139.2% | 49,057 | +27.5% | 0.00% | – |
| Q4 2022 | $108,101 | -54.6% | 38,470 | -33.0% | 0.00% | – |
| Q3 2022 | $238,000 | +14.4% | 57,425 | +11.1% | 0.00% | – |
| Q2 2022 | $208,000 | -22.4% | 51,677 | -4.5% | 0.00% | – |
| Q1 2022 | $268,000 | -28.5% | 54,099 | +0.5% | 0.00% | – |
| Q4 2021 | $375,000 | -60.0% | 53,853 | -42.6% | 0.00% | -100.0% |
| Q3 2021 | $938,000 | +3.4% | 93,751 | +46.6% | 0.00% | 0.0% |
| Q2 2021 | $907,000 | -7.4% | 63,933 | +7.2% | 0.00% | 0.0% |
| Q1 2021 | $979,000 | -18.6% | 59,654 | +2.8% | 0.00% | 0.0% |
| Q4 2020 | $1,202,000 | +69.1% | 58,044 | -37.8% | 0.00% | 0.0% |
| Q3 2020 | $711,000 | -5.7% | 93,385 | +3.2% | 0.00% | 0.0% |
| Q2 2020 | $754,000 | +139.4% | 90,530 | +42.2% | 0.00% | 0.0% |
| Q1 2020 | $315,000 | – | 63,675 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SV Health Investors, LLC | 1,932,607 | $40,643,000 | 15.56% |
| Lamond Capital Partners LLC | 711,533 | $14,964,000 | 15.19% |
| Polaris Venture Management Co. V, L.L.C. | 1,230,009 | $25,867,000 | 11.54% |
| NOTTINGHAM ADVISORS, INC. | 171,985 | $3,617,000 | 0.60% |
| Portolan Capital Management | 122,518 | $2,577,000 | 0.36% |
| SPHERA FUNDS MANAGEMENT LTD. | 160,000 | $3,365,000 | 0.33% |
| Rotella Capital Management, Inc. | 18,461 | $388,000 | 0.32% |
| Monashee Investment Management LLC | 28,834 | $606,000 | 0.29% |
| DRIEHAUS CAPITAL MANAGEMENT LLC | 335,498 | $7,056,000 | 0.24% |
| BAILARD, INC. | 55,000 | $1,157,000 | 0.18% |